Boston Scientific (BSX) vs Tandem Diabetes Care (TNDM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tandem Diabetes Care (TNDM) has outperformed Boston Scientific (BSX) over the past year, gaining 9.1% versus a loss of 56.6%. Over five years, BSX leads with a -4.2% price change compared with -87.4% for TNDM. Boston Scientific is the larger company by market cap ($60.93 billion vs $1.09 billion), about 55.9 times the size.
On valuation, Boston Scientific trades at a lower forward P/E (12.4x vs 98.6x for Tandem Diabetes Care).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSX | TNDM |
|---|---|---|
| Share price | $42.04 | $15.68 |
| Market cap | $60.93B | $1.09B |
| 1-day change | +1.11% | -1.04% |
| YTD return | -56.39% | -27.93% |
| 1-year return | -56.64% | +9.09% |
| 5-year return | -4.19% | -87.36% |
| P/E ratio (TTM) | 17.02 | — |
| Forward P/E | 12.43 | 98.61 |
| EPS (TTM) | $2.47 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $20.07B | — |
| Revenue growth (YoY) | +19.87% | — |
| Net income (latest FY) | $2.89B | — |
| Gross margin | 69.01% | — |
| Operating margin | 18.00% | — |
| Net margin | 14.41% | — |
| 52-week high | $105.65 | $29.65 |
| 52-week low | $41.39 | $12.26 |
| Distance from 52-week high | -60.21% | -47.13% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +42.48% | +77.74% |
| Average volume | 19.71M | 1.99M |
| Shares outstanding | 1.45B | 69.58M |
| Employees | 59,000 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Boston Scientific is about 55.9 times larger than Tandem Diabetes Care by market value ($60.93B vs $1.09B).
- TNDM has outperformed BSX by 65.7 percentage points over the past year.
About Boston Scientific
BSX stock →Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Health Care · Medical/Dental Instruments · 59,000 employees
About Tandem Diabetes Care
TNDM stock →Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
Health Care · Medical/Dental Instruments · 2,500 employees
BSX vs TNDM FAQ
Which is bigger, Boston Scientific or Tandem Diabetes Care?
Boston Scientific (BSX) is larger, with a market capitalization of $60.93B compared with $1.09B for Tandem Diabetes Care (TNDM).
Which stock has performed better over the past year, BSX or TNDM?
TNDM returned +9.09% over the past 12 months, compared with -56.64% for BSX (price return, excluding dividends). Past performance does not predict future results.
Are Boston Scientific and Tandem Diabetes Care in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.